title: New concept for the prevention and treatment of metastatic lymph nodes using chemotherapy administered via the lymphatic network.
abstract: Intravenous chemotherapy has poor access to metastatic lymph nodes (LNs) and is limited by short-lived drug concentrations. Here, we describe the administration of chemotherapy via the lymphatic network as a new concept for the prevention and treatment of metastatic LNs. A metastatic LN can be treated by the injection of drugs into an upstream LN, either the sentinel LN (SLN) or another upstream LN. In a mouse model, tumor cells were inoculated into the subiliac LN (SiLN) to induce metastasis to the proper axillary LN (PALN). Two routes were used for drug delivery to the PALN, namely from the SiLN and from the accessory axillary LN (AALN). We found that tumor masses were formed in lymphatic vessels between the SiLN and PALN. The flow of fluorescent solution injected into the SiLN towards the PALN decreased with tumor mass formation. Delivery from the AALN (free of metastatic tumor cells) to the PALN was identified as an alternative route. Intranodal injection can deliver high concentrations of drugs to secondary metastatic LNs. The study advocates a new concept for the prevention and treatment of metastatic lymph nodes whereby drugs injected into upstream lymph nodes can reach metastatic lymph nodes via the lymphatic network.
authors: Laboratory of Biomedical Engineering for Cancer, Biomedical Engineering Cancer Research Center, Graduate School of Biomedical Engineering, Tohoku University, 4-1 Seiryo, Aoba, Sendai, Miyagi, 980-8575, Japan.
authors: Tetsuya
authors: T
authors: Kodama
authors: Laboratory of Biomedical Engineering for Cancer, Biomedical Engineering Cancer Research Center, Graduate School of Biomedical Engineering, Tohoku University, 4-1 Seiryo, Aoba, Sendai, Miyagi, 980-8575, Japan.
authors: Daisuke
authors: D
authors: Matsuki
authors: Laboratory of Biomedical Engineering for Cancer, Biomedical Engineering Cancer Research Center, Graduate School of Biomedical Engineering, Tohoku University, 4-1 Seiryo, Aoba, Sendai, Miyagi, 980-8575, Japan.|Graduate School of Engineering, Tohoku University, 6-6-05 Aramaki-aza-Aoba, Aoba, Sendai 980-8579, Japan.
authors: Asuka
authors: A
authors: Tada
authors: Laboratory of Biomedical Engineering for Cancer, Biomedical Engineering Cancer Research Center, Graduate School of Biomedical Engineering, Tohoku University, 4-1 Seiryo, Aoba, Sendai, Miyagi, 980-8575, Japan.
authors: Kazu
authors: K
authors: Takeda
authors: Department of Oral and Maxillofacial Surgery, Tohoku University Hospital, 1-1 Seiryo, Aoba, Sendai 980-8575, Japan.
authors: Shiro
authors: S
authors: Mori
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D002244:Carbon / Q000008:administration & dosage; D004195:Disease Models, Animal; D015870:Gene Expression; D017930:Genes, Reporter; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D051677:Histiocytoma, Malignant Fibrous / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D007272:Injections, Intralymphatic; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008198:Lymph Nodes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008207:Lymphatic Metastasis; D042601:Lymphatic Vessels / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic
chemical_list: D000970:Antineoplastic Agents; C028433:chinese ink; D049452:Green Fluorescent Proteins; D002244:Carbon; D008156:Luciferases